OCMS aims to become the industry standard for hybridoma screening. OCMS is non-exclusively licensing the platform and will provide technical support, optimized cell lines, and assay reagents to partners.

Meet the Team


Paul Halpern, J.D.

Managing Member

Paul is the Chief Investment Officer at Versa Capital Management, LLC, a private equity firm that specializes in distressed company turnarounds, and he serves on the boards of a number of Versa’s portfolio companies across the business spectrum. Mr. Halpern received a J.D. from Stanford Law School (with distinction, law review and Order of the Coif) and his B.A. from Reed College (Phi Beta Kappa).


Scott Dessain, M.D., Ph.D.

Chief Scientific Officer

Scott is a physician/scientist who holds the Joseph and Ray Gordon Chair in Clinical Oncology and Research at the Lankenau Medical Center in Wynnewood, PA.  He is the scientific co-founder of Immunome, a cancer immunotherapy company.  He received MD and PhD degrees from Yale University, post-graduate medical training at Brigham and Women’s Hospital and Dana Farber/Partners Cancer Care, followed by post-doctoral studies with Dr. Robert Weinberg at the Whitehead Institute.


Martina Molsbergen

Chief Commercial Officer

Martina is the CEO of the C14 Consulting Group.  She has more than 25 years of business development, marketing and entrepreneurial experience – including more than fifteen years of business development expertise in cutting edge technology tools and products for biotherapeutics, immunotherapies and regenerative medicine. She has mentored and catapulted several cutting-edge platform technologies and products to commercial success, and has helped to launch several start-up companies into the global biotech and pharma arena.